Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2019JAMA Internal MedicineOpen Access

Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

DKDimitrios A. KoutoukidisNational Institute for Health ResearchNANerys M. AstburyUniversity of OxfordKTKate TudorNesta

Discussion

Loading...

Member takes

Implication

Meta-analysis of randomized trials demonstrates improved liver biomarkers following weight loss in fatty liver disease, highlighting the therapeutic role of structured weight reduction.

Key Points

  • To evaluate and quantify the association between weight loss interventions and changes in biomarkers of liver disease among individuals with nonalcoholic fatty liver disease.
  • Systematic review and random-effects meta-analysis adhering to PRISMA guidelines, searching six databases and three trial registries through January 2019.
  • Identified 22 randomized clinical trials (N=2,588; mean age 45 years; ~66% male) comparing weight loss interventions—behavioral programs (n=15), pharmacotherapy (n=6), or surgery (n=1)—with no or lower-intensity interventions over a median duration of 6 months (IQR, 3-8 months).
  • Intensive weight loss interventions produced significantly greater weight reduction (-3.61 kg; 95% CI, -5.11 to -2.12; I2=95%) and alanine aminotransferase decreases (-9.81 U/L; 95% CI, -13.12 to -6.50; I2=97%).
  • Interventions were significantly associated with reductions in liver steatosis (standardized mean difference: -1.48; 95% CI, -2.27 to -0.70; I2=94%), histologic NAFLD activity score (-0.92; 95% CI, -1.75 to -0.09; I2=95%), and presence of nonalcoholic steatohepatitis (OR, 0.14; 95% CI, 0.04-0.49; I2=0%).
  • No statistically significant improvement was observed for histologic liver fibrosis (-0.13; 95% CI, -0.54 to 0.27; I2=68%).

Cite This Study

Koutoukidis et al. (2019) studied this question.

synapsesocial.com/papers/6a705622e5469ee92be11452https://doi.org/10.1001/jamainternmed.2019.2248
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up2014 · 2,312 citations
  2. 2Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients2016 · 354 citations
  3. 3The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis2015 · 915 citations
  4. 4A century of trends in adult human height2016 · 1,562 citations